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bstract
Despite numerous evidences for neurotoxicity of overexpressed-synuclein, a protective function was suggested for endogenous-synuclein
nd other members of the synuclein family. This protective role is most important for and evident in presynaptic terminals, where synucleins
re normally accumulated. However, mice lacking synucleins display no adverse phenotype. In particular, no significant changes in striatal
opamine metabolism and only subtle deficit of dopaminergic neurons in the substantia nigra were found in juvenile or adult mice. To assess
hether aging and synuclein deficiency may have additive detrimental effect on the nigrostriatal system, we studied dopaminergic neurons of
he substantia nigra and their striatal synapses in 24–26-month-old -synuclein and -synuclein null mutant mice. Significant ∼36% reduction
f the striatal dopamine was found in aging -synuclein, but not -synuclein null mutant mice when compared to age-matching wild type
ice. This was accompanied by the reduction of TH-positive fibers in the striatum and decrease of striatal levels of TH and DAT. However, no
rogressive loss of TH-positive neurons was revealed in the substantia nigra of synuclein-deficient aging animals. Our results are consistent
ith a hypothesis that -synuclein is important for normal function and integrity of synapses, and suggest that in the aging nervous system
ysfunction of this protein could become a predisposition factor for the development of nigrostriatal pathology.
© 2008 Elsevier Inc.
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. Introduction
The decade of intensive studies that followed the origi-
al demonstration of direct links between -synuclein and
arkinson’s disease (Polymeropoulos et al., 1997; Spillantini
t al., 1997) revealed structural, functional and metabolic
roperties of this protein that might be responsible for
ts role in the development of Parkinson’s and other neu-
odegenerative disorders, now known as synucleinopaties.
 All animal work was carried in accordance with the United Kingdom
nimals (Scientific Procedures) Act (1986).
∗ Corresponding author. Tel.: +44 29 20879068; fax: +44 29 20874116.
E-mail address: BuchmanVL@cardiff.ac.uk (V.L. Buchman).
1 Present address: GE Healthcare, R & D, The Grove Centre, White Lion
oad, Amersham, Buckinghamshire HP7 9LL, United Kingdom.
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Open access under CC BY license.evertheless, the question about exact mechanism of -
ynuclein involvement in neurodegeneration is still wide
pen. Histopathological observations together with high
ropensity of -synuclein to aggregate, which could be fur-
her increased by certain causative mutations, led to an
ntuitive hypothesis that aggregation into large insoluble fila-
ents, which become major constituents of Lewy bodies and
ther inclusions, is the primary cause of neurodegenerative
hanges (Trojanowski et al., 1998; Spillantini and Goedert,
000; Galvin et al., 2001). However, further clinical and
xperimental studies questioned the importance of the final
roducts of -synuclein aggregation, fibrils or filaments, for
he cytotoxic effect of mutated or overexpressed -synuclein
Mori et al., 1998; Saha et al., 2000; Volles et al., 2001; Gosavi
t al., 2002; Volles and Lansbury, 2002). It has been suggested
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hat although enhanced aggregation is a prerequisite for -
ynuclein cytotoxicity, the toxic effect should be attributed
ot to fibrils but to soluble intermediates of aggregation pro-
ess, oligomers or protofibrils (reviewed in Dev et al., 2003;
olles and Lansbury, 2003). Moreover, a swing of aggrega-
ion kinetics in favour of the final steps of the process could
educe intracellular concentration of these toxic -synuclein
pecies by precipitating and trapping them within the insol-
ble deposits. Aggregation products could be cleared up to a
ertain extent, by intracellular systems (e.g. autophagosome
nd lysosome) that are different from systems metabolising
oluble proteins (e.g. proteasome), which increases the abil-
ty of cells to combat the increased production of potentially
oxic proteins like -synuclein (Ciechanover and Brundin,
003; Webb et al., 2003; Cuervo et al., 2004; Lee et al., 2004;
ideout et al., 2004). Although toxicity of aggregation inter-
ediates is currently widely accepted as the major step in the
evelopment of -synuclein-induced pathology, other mech-
nisms may also play an important role in this process. One
ignificant consequence of aggregation or aberrant intracel-
ular trafficking of -synuclein is depletion of its pool at the
ntracellular sites where this protein is normally localised,
rimarily in the presynaptic terminals. The outcome of the
esulting loss-of-function is not apparent because above all
he function itself is still not defined. However, recent stud-
es clearly demonstrated the importance of -synuclein in
rotection from at least some types of synaptic dysfunction
nd consequent neurodegeneration (Chandra et al., 2005).
his function of -synuclein could be revealed only in a case
hen certain other protective mechanisms fail, suggesting
n auxiliary role of this protein in neuroprotection. Studies
f various tissue culture models also demonstrated that -
ynuclein could act as a protective factor but only in particular
onditions and types of cells (reviewed in Dev et al., 2003).
oreover, animals lacking functional -synuclein gene as
he result of either spontaneous deletion or targeted inactiva-
ion do not show any signs of degeneration in their nervous
ystem (Abeliovich et al., 2000; Specht and Schoepfer, 2001;
abin et al., 2002; Dauer et al., 2002; Schluter et al., 2003).
simple functional compensation by other members of the
amily, -synuclein and -synuclein, could not explain this
ack of pathological changes because neither double nor triple
ynuclein adult null-mutant mice develop adverse phenotype
Chandra et al., 2004; Robertson et al., 2004; Papachroni et
l., 2005 and our unpublished observations). However, no
tudies of the nervous system of aging synuclein null mutant
ice have been carried out so far. Aging is associated with
unctional decline of many protective systems within cells.
n particular, age-related changes in the nigrostriatal system
ould predispose to the development of Parkinson’s disease
Phinney et al., 2006; Chu and Kordower, 2007; Collier et
l., 2007). It is feasible that the absence of auxiliary pro-
ective factors like synucleins might exacerbate pathological
hanges related to the senescence of the nervous system. This
s consistent with clinical data suggesting that aging is the
ajor risk factor for developing idiopathic synucleinopathies.
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We studied the nigrostriatal system of aging synuclein
ull mutant mice and demonstrated that the absence of -
ynuclein but not -synuclein leads to the substantial decline
f dopamine level and decrease of expression of certain
ynaptic markers in the striatum without reduction of the
umber of dopaminergic neurons in the substantia nigra pars
ompacta (SNpc).
. Methods
.1. Animals
Generation and maintenance of colonies of -synuclein
nd -synuclein null mutant mice on pure C57Bl6J genetic
ackground was described previously (Ninkina et al., 2003;
obertson et al., 2004). Experimental cohorts for this study
ere formed from litters produced by intercrossing heterozy-
ous animals. After weaning and genotyping the null mutant
nd wild type male littermates were housed one per cage with
ree access to water and food until they reach age of 24–26
onths. Animals (for simplicity refer in the manuscript as
-year-old mice) were sacrificed by cervical dislocation, and
issues were collected and coded. Therefore, individuals that
erformed all further analyses were unaware of the sample
enotype. Animal performance in an accelerating rotarod test
as assessed as described previously (Robertson et al., 2004).
.2. Neuronal cell counts
For quantification of neurons, brains of age-matching wild
ype, -synuclein and -synuclein null mutant mice were
ollected, fixed, processed, embedded and stained simul-
aneously. 8-m-thick sections were cut using a HM 310
icrotome (Microm International) and mounted onto poly-
-lysine coated slides. The borders of the substantia nigra
nd ventral tegmental area (VTA) on histological sections
ere outlined using distribution atlas of tyrosine hydroxy-
ase (TH)-positive cells (Hokfelt et al., 1984). The number
f dopamine positive neurons in these two brain regions
f 2-year-old animals was assessed by stereological count-
ng of cells stained for TH on serial histological sections as
escribed previously (Robertson et al., 2004). Briefly, the first
ection for counting was randomly chosen from the first 10
ections that included SNpc/VTA region. Starting from this
ection, every TH-positive cell with a clearly seen nucleus
as counted on the every tenth section through the whole
egion. The Axiovision imaging program (Carl Zeiss Vision)
as employed to measure diameters of 50 nuclei of dopamin-
rgic neurons in the SNpc and 50 nuclei of dopaminergic
eurons in the VTA of every mouse brain included in this
tudy. The nuclei were chosen randomly and the distance
easured as the horizontal length as they appeared on screen.
mean was calculated for each animal and used for Aber-
rombie’s correction (Abercrombie, 1946) to obtain an actual
umber of TH positive cells in the structure.
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.3. HPLC analysis of striatal dopamine and its
etabolites
Striata of 2-year-old mice were dissected, immediately
nap-frozen in liquid nitrogen and kept at −80 ◦C. Extraction
nd HPLC analysis of striatal dopamine and its metabo-
ites was carried out as described in our previous publication
Robertson et al., 2004).
.4. Density of immunostaining in striatum
Coronal brain sections at the level of striatum were
mmunostained with antibody against tyrosine hydroxylase
mouse monoclonal, clone TH-2, Sigma, diluted 1:5000).
ignal detection was carried out according to previously
escribed protocol (Benno et al., 1982). In each experiment,
ll sections were processed and immunostained simultane-
usly, and special care was taken to assure that the length of
he development step was the same for each section. Images
f stained sections were obtained using AlphaImager 2200
nd densities of staining in the dorsal striatum were analyzed
sing AlphaEase 2200 Analysis Software (AlphaInnotech
orporation). Background staining outside the striatum was
ubtracted to yield a value for the area of positive staining.
eft and right striata were analyzed separately at three simi-
ar plane sections along the rostra-caudal axis (Bregma 0.26,
.74 and 1.18 mm, judged by typical anatomical landmarks)
or at least four brains per genotype.
.5. Western blot analysis
SDS polyacrylamide gel electrophoresis (SDS–PAGE),
estern blot transfer to Hybond-P filters (GE Healthcare),
locking, incubation with antibodies, washing and detection
sing enhanced chemiluminescence (ECL or ECL+) tech-
iques were carried out as described previously (Buchman
t al., 1998; Robertson et al., 2004). Intensities of bands
btained using AlphaImager 2200 were analysed using
lphaEase 2200 Analysis Software (AlphaInnotech Cor-
oration). To extract total striatal proteins, each striatum
as homogenized in 150l of SDS-PAGE loading buffer
ollowed by heating in the boiling water bath for 5 min.
mmunoblotting with mouse monoclonal antibody against
-actin (clone AC-15, Sigma) was carried out using total
triatal protein samples diluted to achieve intensity of actin
ands within a linear detection range. The original sam-
les were normalized according to results of actin bands
ensitometry and equal loading was further confirmed by
mmunoblot analysis of normalized samples with an anti-
ody against another housekeeping protein, either -tubulin
mouse monoclonal, clone DM 1A, Sigma) or glyceraldehyde
-phosphate dehydrogenase (GAPDH, mouse monoclonal,
lone 6C5, Santa Cruz Biotechnology). Normalized samples
ere run on 8%, 12% or 16% SDS-PAAG depending on
izes of proteins to be analyzed, transferred to a nylon filter
nd probed with antibodies against various synaptic mark-
n
2
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rs. Antibodies against -synuclein (mouse monoclonal,
lone 42, BD Transduction Laboratories, diluted 1:500),
-synuclein (mouse monoclonal, clone 8, BD Transduc-
ion Laboratories, diluted 1:5000), TH (mouse monoclonal,
lone TH-2, Sigma, diluted 1:5000), dopamine transporter
DAT, rabbit polyclonal, Sigma, diluted 1:500), amphiphysin
mouse monoclonal, clone 15, BD Transduction Laborato-
ies, diluted 1:10 000), synaptophysin (mouse monoclonal,
lone 2, BD Transduction Laboratories, diluted 1:25 000),
ynaptotagmin (mouse monoclonal, clone ASV48, QED,
iluted 1:5000), SNAP-25 (mouse monoclonal, clone 20,
D Transduction Laboratories, diluted 1:1000), cysteine
tring proteins (CSP, rabbit polyclonal, Santa Cruz, diluted
:1000), glial fibrillary acidic protein (GFAP, rabbit poly-
lonal, Sigma, diluted 1:500), Rab3 (mouse monoclonal,
lone 9, BD Transduction Laboratories, diluted 1:2500),
abphilin-3A (mouse monoclonal, clone 47, BD Transduction
aboratories, diluted 1:1000) and sec8 (mouse monoclonal,
lone 14, BD Transduction Laboratories, diluted 1:1000)
ere used. After probing with antibodies against synaptic
arkers each filter was re-probed with an antibody against
ne of the housekeeping proteins described above to confirm
niform efficiency of protein transfer. The ratio of intensi-
ies of a studied protein band and housekeeping protein band
as calculated for each filter and the mean of these ratios for
ild type animal samples was considered as 100%. All other
atios were expressed as fractions of this mean allowing to
ool together results obtained for each protein from different
estern blot filters. Each sample was analyzed for expression
f each protein on at least two different Western blot filters
ith different combinations of other samples.
. Results
.1. Reduced dopamine content in the striatum of aging
-synuclein but not γ-synuclein null mutant mice
Levels of dopamine and its metabolites in the striatum
f aging wild type and null mutant mice were measured
sing standard HPLC analysis as described in Section 2.
arked reduction of striatal dopamine was detected in 2-
ear-old -synuclein null mutant mice (63.8% of the wild
ype level) but not -synuclein null mutant mice (96.4% of
he wild type level) when compared to 2-year-old wild type
ice (Fig. 1). However, DOPAC levels were the same for
ll three genotypes and although HVA levels in -synuclein
ull mutant mice were lower than in two other geno-
ype groups the difference was not statistically significant
Fig. 1). Consequently, metabolite/dopamine ratios, particu-
arly DOPAC/dopamine, were increased in -synuclein null
utant mice (Table 1).
However, the observed reduction of striatal dopamine was
ot sufficient to impede motor coordination and balance of
-year-old -synuclein null mutant mice, as could be judged
rom their performances in accelerated rotarod (Fig. 2C) that
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Fig. 1. Dopamine and its metabolite levels in striatum of 2-year-old wild type and synuclein null mutant mice. Striatal concentrations (ng/mg protein) of
dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in mutant animals were normalized to corresponding mean values for
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gamma−/−) animals from two separate experimental cohorts are shown. S
utant mice (*, p < 0.05, one-way ANOVA with post hoc Fisher’s protected
as not different from performances of 2-year-old wild type
ice.
.2. No progressive loss of dopaminergic neurons in
Npc of aging α-synuclein or γ-synuclein null mutant
ice
In the previous study we have demonstrated that on
ure C57Bl6 genetic background both -synuclein and -
ynuclein null mutant adult mice have small but statistically
ignificant deficit of TH-positive neurons in SNpc compar-
ng to their wild type littermates (Robertson et al., 2004). To
ssess whether the observed decrease of striatal dopamine
n aging -synuclein null mutant was caused by progres-
ive loss of dopaminergic neurons projecting their axons to
he striatum, we counted number of TH-positive neurons in
Npc of 2-year-old wild type, -synuclein and -synuclein
ull mutant mice. In both groups of null mutant mice these
eurons morphologically looked as healthy as in wild type
ice (data not shown). Fig. 2A demonstrates that although
oth -synuclein and -synuclein null mutant mice have less
d
l
t
o
ig. 2. The number of dopaminergic neurons in the substantia nigra and ventral te
heir performance in accelerated rotarod test. Bar chart shows means ± S.E.M. of tot
ounted separately in left and right SNpc and VTA of 9 wild type (WT), 9 -synuc
nimals. Statistic analysis revealed significantly reduced number of neurons in SN
< 0.01, one-way ANOVA with post hoc Fisher’s protected t-test) and no difference
anel C shows results of an accelerated rotarod test that demonstrated no significan
ice.T), 11 -synuclein null mutant (alpha−/−) and 10 -synuclein null mutant
al analysis revealed significant decrease of striatal DA in -synuclein null
but no differences for other neurochemicals and genotypes (p > 0.05).
opaminergic neurons than their wild type littermates at the
ge of 2 years, these differences (16.5% decrease for -
ynuclein and 13.6% decrease for -synuclein null mutants)
re very similar to those previously reported for 5 day and
-month-old animals (Robertson et al., 2004). In agreement
ith previously reported results, we did not find significant
ifference in number of dopaminergic neurons in VTA of
hree studied groups of 2-year-old animals (Fig. 2B).
.3. Certain dopaminergic and synaptic marker proteins
re downregulated in the striatum of aging α-synuclein
ull mutant mice
Reduced levels of the striatal dopamine in the absence of
opaminergic neuron loss in SNpc might reflect the devel-
pment of synaptic dysfunction in the nigrostriatal system
f aging -synuclein null mutant mice. To evaluate the
opaminergic innervation of the striatum we stained histo-
ogical section of this brain region with antibodies against
yrosine hydroxylase. The number of stained fibers was obvi-
usly reduced in the dorsal striatum of aging -synuclein
gmental area of 2-year-old wild type and synuclein null mutant mice and
al number of TH-positive neurons in SNpc (A) and VTA (B). Neurons were
lein null mutant (alpha−/−) and 10 -synuclein null mutant (gamma−/−)
pc for both types of mutant mice when compared to wild type mice (*,
in number of VTA neurons between all three groups (p > 0.05). Bar chat in
t difference (p > 0.05) in latency to fall between three groups of 2-year-old
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Table 1
Metabolite to dopamine concentration ratios in striata of 2-year-old wild
type, -synuclein null mutant and -synuclein null mutant mice.
Genotype DOPAC/dopamine
(mean ± S.E.M.)
HVA/dopamine
(mean ± S.E.M.)
Wild type 0.20 ± 0.01 0.06 ± 0.01

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Table 2
Levels of protein markers in striata of 2-year-old wild type, -synuclein null
mutant and -synuclein null mutant mice expressed as % of wildtype mean.
Marker Genotype
Wild type -Synuclein −/− -Synuclein −/−
TH 100 ± 3.77 70.9 ± 8.09** 98 ± 9.14
DAT 100 ± 8.74 63.2 ± 7.96* 139.5 ± 11.32*
Amphiphysin 100 ± 6.10 56.3 ± 12.24** 94.6 ± 6.91
Synaptotagmin 100 ± 6.24 71.5 ± 9.96** 96.5 ± 8.80
Synaptophysin 100 ± 5.28 104.8 ± 6.93 91.2 ± 5.09
SNAP25 100 ± 8.79 97 ± 14.98 115 ± 7.72
Rab3 100 ± 17.23 83.2 ± 13.62 117.5 ± 12.62
Sec8 100 ± 7.20 86.6 ± 5.37 89.6 ± 14.52
CSP 100 ± 2.75 108.9 ± 7.37 109.3 ± 7.43
GFAP 100 ± 3.93 122.0 ± 9.09* 122.7 ± 7.36*-synuclein −/− 0.31 ± 0.04* 0.08 ± 0.01
-synuclein −/− 0.22 ± 0.02 0.07 ± 0.01
* p < 0.05, one-way ANOVA with post hoc Fisher’s protected t-test.
ull mutant mice when compared to the striatum of wild type
r -synuclein null mutant mice of the same age (Fig. 3A).
he average density of TH staining was also found to be
ower in the dorsal striatum of these mice (Fig. 3B). To
onfirm these observations we analyzed TH in total pro-
ein samples extracted from the striatum of 2-year-old wild
ype, -synuclein or -synuclein null mutant mice by West-
rn blotting. Consistently with immunohistochemical data,
he substantial reduction of TH was observed in the stria-
ig. 3. Immunohistochemical detection of tyrosine hydroxylase in the stria-
um of 2-year-old wild type and synuclein null mutant mice. Representative
icrophotographs of coronal sections of wild type, -synuclein and -
ynuclein null mutant mouse brains at the Bregma 1.18 mm level stained with
ntibody against TH (top panels) and high magnification images that reveal
H-positive fibers in the dorsal striatum (bottom panes, scale bar = 10m)
re shown (A). Bar chart shows means ± S.E.M. of TH staining densities (B).
ne-way ANOVA with post hoc Fisher’s protected t-test demonstrated that
he density is significantly lower in the striatum of -synuclein (alpha−/−)
ull mutant mice when compared to wild type (WT) mice (**p < 0.01) or
-synuclein (gamma−/−) null mutant mice (*p < 0.05).
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m* p < 0.05 and **p < 0.01, one-way ANOVA with post hoc Fisher’s pro-
ected t-test.
um of aging -synuclein but not -synuclein null mutant
ice when compared with control wild type mice (Fig. 4 and
able 2). Another marker of dopaminergic terminals, DAT,
as also downregulated in aging -synuclein null mutant
ice but upregulated in -synuclein null mutant mice. Two
ynaptic proteins that are not specific to dopaminergic neu-
ons, namely amphiphysin and synaptotagmin, were also
ound less abundant in the striatum of -synuclein than in
-synuclein null mutant or wild type mice, whereas no sig-
ificant differences were revealed for SNAP-25, Sec8, Rab3,
abphilin-3A, CSP and synaptophysin (Fig. 4 and Table 2). A
light increase of an astroglial marker GFAP was observed in
he striatum of both -synuclein and -synuclein null mutant
ice.
.4. Deletion of α-synuclein or γ-synuclein does not
ffect β-synuclein abundance in the striatum of aging
ice
It has been previously suggested that other members of the
ynuclein family might compensate the absence of an inacti-
ated synuclein and compensatory increase of the expression
f remaining member(s) of the family in certain brain regions
f synuclein null mutant mice has been reported (Chandra et
l., 2004; Robertson et al., 2004; Kuhn et al., 2007). To check
f observed changes in the striatum of 2-year-old -synuclein
ull mutant mice could be linked with age-related reduction
f -synuclein and, particularly, -synuclein in the brain of
hese mice, we assessed striatal levels of these proteins by
estern blotting. Although -synuclein is not abundant in
ging striatum and was barely detectable on Western blots,
o changes of this protein level were observed in the striatum
f 2-year-old -synuclein null mutant mice (data not shown).
uch more abundant -synuclein was easily detectable but
o difference in the level of this protein in the striatum of
-year-old wild type, -synuclein or -synuclein null mutant
ice was found (Fig. 5).
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nd -synuclein null mutant mice are shown. Samples extracted from each d
escribed in Section 2. Equal amount of total protein was loaded on each la
. Discussion
In human populations the rate of idiopathic Parkinson’s
isease as well as many other neurodegenerative condi-
ions strongly correlates with old age. However, molecular
echanisms that make cells in the ageing nervous system,
articularly dopaminergic neurons of the nigrostriatal sys-
em, progressively more vulnerable to pathological changes
re still not well defined. Recent advances in our knowledge
bout pathogenesis of human neurodegenerative disorders
uggest that combinations of various factors are required for
he development of pathological changes that lead to mani-
estation of a disease. -synuclein dysfunction is one of the
est studied factors implicated in the aetiology and patho-
e
o
b
2e Western blots of striatal proteins extracted from wild type, -synuclein
d striatum individually were first normalized using anti--actin antibody as
robed with antibody against proteins shown left to each horizontal panel.
enesis of Parkinson’s disease although exact mechanism
f this protein involvement in the development and progres-
ion of neurodegenerative changes is not clearly understood.
s discussed in Section 1, recent evidences suggest that the
oss of functional-synuclein could enhance neuronal and/or
ynaptic pathology induced by other factors. However, this
oncept is not directly supported by studies of mice lack-
ng -synuclein. No sign of neurodegeneration was found in
he nervous system of adult -synuclein null mutant mice
Abeliovich et al., 2000; Specht and Schoepfer, 2001; Cabin
t al., 2002; Dauer et al., 2002; Schluter et al., 2003), more-
ver dopaminergic neurons of these animals were found to
e less sensitive to neurotoxic effects of MPTP (Dauer et al.,
002; Schluter et al., 2003; Drolet et al., 2004; Robertson
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Fig. 5. -synuclein in the striatum of 2-year-old mice. (A) Bar chart shows means ± S.E.M. of -synuclein/GAPDH band density ratios normalized to the mean
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eatio for wild type animal samples as 100%. Individual striatum samples fro
ifferences were found between groups (p > 0.05). (B) A representative Wes
rom three striata for each genotype. The filters were probed simultaneously
t al., 2004; Fornai et al., 2005), 6-OHDA (Alvarez-Fischer
t al., 2008) and paraquat (our unpublished observations).
o explain these discrepancies we have suggested that in
rder to survive without -synuclein, dopaminergic neurons
f substantia nigra pars compacta should keep activity of
ome pro-survival pathways at elevated level. This makes
eurons more robust to certain environmental challenges but
nly until they are able to sustain required level of compen-
ation. In this study we used old (≥2 years of age) synuclein
ull mutant mice as a model system to address the question if
ging could be a factor that unveil any deteriorating effect(s)
f synuclein deficiency on the nigrostriatal system.
In our previous study a small but statistically significant
euronal deficit has been revealed in SNpc of adult -
ynuclein and -synuclein null mutant mice comparing with
ild type mice (Robertson et al., 2004). We found no pro-
ressive loss of dopaminergic neurons in SNpc of old animals
acking either of these two synucleins, suggesting that the
bsence of these proteins does not make dopaminergic neu-
ons more susceptible to death in the aging substantia nigra.
owever, in the striatum of aging -synuclein null mutant
ice we observed changes that suggested impaired function
f dopaminergic neuron synapses. A significant depletion
f striatal dopamine in 2-year-old -synuclein null mutant
ice that have not been seen in younger 9-month-old ani-
als (Robertson et al., 2004) indicates age-associated partial
oss of striatal dopamine neurotransmission triggered by the
bsence of -synuclein but not -synuclein. Most probably it
s due to reduction of the number of functional dopaminergic
ynapses, while significantly increased DOPAC/dopamine
nd slightly increased HVA/dopamine ratio reflect increased
opamine turnover. Similar increase of metabolite/dopamine
atios has been reported in various animal models at the recov-
ry stage that followed lesion of the nigrostriatal system and
s believed to reflect a compensatory increase of dopamine
urnover in remaining functional synapses (Hefti et al., 1985;
ltar et al., 1987; Rose et al., 1989; Pifl and Hornykiewicz,
e
t
o
e9 animals per genotype were analysed by Western blotting. No significant
t shows analysis of mixtures of the equal amounts of total protein samples
nti--synuclein and anti-GAPDH antibody.
006). Reduced density of TH-positive fibers and lower lev-
ls of TH and DAT, markers of dopaminergic synapses, that
e have observed in the striatum of 2-year-old -synuclein
ull mutant compared to wild type or -synuclein null mutant
ice are consistent with the idea that the loss of -synuclein
unction causes partial loss of dopaminergic synapses in the
ging striatum. For the majority of studied general presynap-
ic proteins no significant changes in expression levels were
ound, suggesting that other types of synapses in the stria-
um of aging -synuclein null mutant mice are not affected.
he lower level of synaptotagmin is probably not associated
ith age-related changes because reduction of synaptotag-
in mRNA expression has been found previously in various
rain regions of young-synuclein null mutant mice (Kuhn et
l., 2007). A reason for the reduction of amphiphysin is not
lear and might be associated with downregulation of this
rotein expression in aging nervous system of -synuclein
ull mutant mice.
Results of our previous studies indicated that both -
ynuclein and -synuclein are required for efficient survival
f dopaminergic neurons during critical periods of the sub-
tantia nigra development (Robertson et al., 2004). In another
tudy the synaptoprotective role of -synuclein during early
ostnatal development has been demonstrated (Chandra et al.,
005) but the involvement of -synuclein in this process has
ot been assessed. Here we demonstrated that -synuclein
ut not -synuclein is required for effective protection of
opaminergic synapses in aging striatum. This is not surpris-
ng because the level of-synuclein in the striatum is very low
omparing to the level of-synuclein (Li et al., 2002; Ninkina
t al., 2003). Neuroprotective properties of the third member
f the family,-synuclein, have been demonstrated in various
xperimental systems (Hashimoto et al., 2001, 2004; da Costa
t al., 2003; Park and Lansbury, 2003; Fan et al., 2006) and
he increased levels of this protein detected in the midbrain
f mice lacking -synuclein or/and -synuclein (Robertson
t al., 2004) might be linked with neuroprotection. In the
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triatum, -synuclein, similarly to -synuclein, was found
redominantly in presynaptic terminals (Shibayama-Imazu
t al., 1993; Nakajo et al., 1994; Li et al., 2002; Schluter et
l., 2003; Chandra et al., 2004). Therefore, it was feasible
o check if the observed changes in the striatum of aging -
ynuclein null mutant mice correlated with a reduced level
f -synuclein. However, no difference in the level of this
rotein in the striatum of all three studied groups of age-
ng mice was observed, suggesting limited, if any, role of
-synuclein in the development of these changes. Further
etailed studies are required to reveal the exact molecular
rocesses, which functional decline in the striatum of aging
nimals increases the sensitivity of dopaminergic synapses
o -synuclein deficiency.
In conclusion, the results of our studies are in agreement
ith a proposed synaptoprotective role of endogenous -
ynuclein. We have shown that the absence of this protein
akes striatal dopaminergic synapses more vulnerable to
hanges associated with aging of the nervous system. As
he first demonstration of an additive effect of aging and
-synuclein depletion on the induction of synaptic dysfunc-
ion in the nigrostriatal system this observation casts new
ight on the molecular and cellular mechanisms involved in
athogenesis of idiopathic Parkinson’s disease.
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